Objectives Pregnancy in SLE is associated with increased maternal and fetal risks but its impact on irreversible organ damage ...

Objective The Systemic Immune-Inflammation Index (SII) is an accessible haematological marker reflecting systemic ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Objective To assess real-world treatment regimens and patterns in childhood-onset SLE (cSLE) and adult-onset SLE (aSLE) cohorts, including similarities in treatments, duration of use and adherence.

Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated ...

Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, ...

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist. Clinical trials in SLE have not consistently demonstrated an increased ...

Objectives SLE is characterised by unpredictable flares and periods of quiescence. Currently, the mechanisms driving flares remain incompletely understood. Type I interferon (IFN) signalling is ...

Objective To explore the efficacy of initial treatment of newly diagnosed childhood-onset lupus nephritis (cLN) with combination of belimumab and either cyclophosphamide, mycophenolate mofetil, ...

Objectives Systemic lupus erythematosus (SLE) is a highly heterogeneous disease, and B cell abnormalities play a central role in the pathogenesis of SLE. Long non-coding RNAs (lncRNAs) have also been ...

Objectives Dysregulated IRF5 activity drives type I interferon, pathogenic cytokine production, and B cell activation and differentiation downstream of TLR7/8/9 signaling, contributing to systemic ...

Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective ...